Renal Sympathetic Denervation for Hypertension

Kearney P.M. Whelton M. Reynolds K. Muntner P. Whelton P.K. He J.

Global burden of hypertension: analysis of worldwide data.

Lancet Lond Engl. 365: 217-223https://doi.org/10.1016/S0140-6736(05)17741-1Kirkland E.B. Heincelman M. Bishu K.G. et al.

Trends in Healthcare Expenditures Among US Adults With Hypertension: National Estimates, 2003-2014.

J Am Heart Assoc. 7e008731https://doi.org/10.1161/JAHA.118.008731Muntner P. Carey R.M. Gidding S. et al.

Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.

J Am Coll Cardiol. 71: 109-118https://doi.org/10.1016/j.jacc.2017.10.073Zhou B. Danaei G. Stevens G.A. et al.

Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys.

The Lancet. 394: 639-651https://doi.org/10.1016/S0140-6736(19)31145-6Kannan A. Medina R.I. Nagajothi N. Balamuthusamy S.

Renal sympathetic nervous system and the effects of denervation on renal arteries.

World J Cardiol. 6: 814-823https://doi.org/10.4330/wjc.v6.i8.814

Role of renal sensory nerves in physiological and pathophysiological conditions.

Am J Physiol Regul Integr Comp Physiol. 308: R79-95https://doi.org/10.1152/ajpregu.00351.2014Schlaich M.P. Sobotka P.A. Krum H. Lambert E. Esler M.D.

Renal sympathetic-nerve ablation for uncontrolled hypertension.

N Engl J Med. 361: 932-934https://doi.org/10.1056/NEJMc0904179Smithwick R.H. Thompson J.E.

Splanchnicectomy for essential hypertension; results in 1,266 cases.

J Am Med Assoc. 152: 1501-1504https://doi.org/10.1001/jama.1953.03690160001001

Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy.

Am J Surg. 75: 48-68https://doi.org/10.1016/0002-9610(48)90284-0Krum H. Schlaich M. Whitbourn R. et al.

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Lancet Lond Engl. 373: 1275-1281https://doi.org/10.1016/S0140-6736(09)60566-3

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339

Krum H. Schlaich M.P. Sobotka P.A. et al.

Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Lancet Lond Engl. 383: 622-629https://doi.org/10.1016/S0140-6736(13)62192-3Esler M.D. Böhm M. Sievert H. et al.

Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Eur Heart J. 35: 1752-1759https://doi.org/10.1093/eurheartj/ehu209Rippy M.K. Zarins D. Barman N.C. Wu A. Duncan K.L. Zarins C.K.

Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety.

Clin Res Cardiol Off J Ger Card Soc. 100: 1095-1101https://doi.org/10.1007/s00392-011-0346-8Bhatt D.L. Kandzari D.E. O’Neill W.W. et al.

A Controlled Trial of Renal Denervation for Resistant Hypertension.

N Engl J Med. 370: 1393-1401https://doi.org/10.1056/NEJMoa1402670Bakris G.L. Townsend R.R. Flack J.M. et al.

12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.

J Am Coll Cardiol. 65: 1314-1321https://doi.org/10.1016/j.jacc.2015.01.037Kandzari D.E. Bhatt D.L. Brar S. et al.

Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.

Eur Heart J. 36: 219-227https://doi.org/10.1093/eurheartj/ehu441Kandzari D.E. Bhatt D.L. Sobotka P.A. et al.

Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.

Clin Cardiol. 35: 528-535https://doi.org/10.1002/clc.22008Sakakura K. Ladich E. Cheng Q. et al.

Anatomic assessment of sympathetic peri-arterial renal nerves in man.

J Am Coll Cardiol. 64: 635-643https://doi.org/10.1016/j.jacc.2014.03.059Mahfoud F. Tunev S. Ewen S. et al.

Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation.

J Am Coll Cardiol. 66: 1766-1775https://doi.org/10.1016/j.jacc.2015.08.018Mahfoud F. Schmieder R.E. Azizi M. et al.

Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

Eur Heart J. 38: 3272-3281https://doi.org/10.1093/eurheartj/ehx215

Catheter-Based Renal Nerve Ablation as a Novel Hypertension Therapy.

Hypertension. 71: 383-388https://doi.org/10.1161/HYPERTENSIONAHA.117.08928Townsend R.R. Mahfoud F. Kandzari D.E. et al.

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Lancet Lond Engl. 390: 2160-2170https://doi.org/10.1016/S0140-6736(17)32281-XBöhm M. Mahfoud F. Townsend R.R. et al.

Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.

Eur Heart J. 40: 743-751https://doi.org/10.1093/eurheartj/ehy871Kandzari D.E. Böhm M. Mahfoud F. et al.

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Lancet Lond Engl. 391: 2346-2355https://doi.org/10.1016/S0140-6736(18)30951-6Mahfoud F. Kandzari D.E. Kario K. et al.

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.

The Lancet. 399: 1401-1410https://doi.org/10.1016/S0140-6736(22)00455-X

Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. doi:10.4244/EIJV8I1A10

Daemen J. Mahfoud F. Kuck K.H. et al.

Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study.

J Hypertens. 37: 1906-1912https://doi.org/10.1097/HJH.0000000000002120Mauri L. Kario K. Basile J. et al.

A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.

Am Heart J. 195: 115-129https://doi.org/10.1016/j.ahj.2017.09.006Azizi M. Schmieder R.E. Mahfoud F. et al.

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Lancet Lond Engl. 391: 2335-2345https://doi.org/10.1016/S0140-6736(18)31082-1Azizi M. Schmieder R.E. Mahfoud F. et al.

Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.

Circulation. 139: 2542-2553https://doi.org/10.1161/CIRCULATIONAHA.119.040451Azizi M. Daemen J. Lobo M.D. et al.

12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.

JACC Cardiovasc Interv. 13: 2922-2933https://doi.org/10.1016/j.jcin.2020.09.054Mahfoud F. Bloch M.J. Azizi M. et al.

Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial.

EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 17: e1024-e1032https://doi.org/10.4244/EIJ-D-21-00295Azizi M. Sanghvi K. Saxena M. et al.

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.

The Lancet. 397: 2476-2486https://doi.org/10.1016/S0140-6736(21)00788-1Kario K. Hoshide S. Mizuno H. et al.

Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis: Practitioner-Based Nationwide JAMP Study.

Circulation. 142: 1810-1820https://doi.org/10.1161/CIRCULATIONAHA.120.049730

Kirtane AJ. Six-month outcomes of a randomized trial of renal denervation versus a sham procedure: blinded medication titration for resistant hypertension in the RADIANCE-TRIO trial. Presented at: TCT 2021; November 4, 2021; Orlando, FL.

Kario K, Yokoi Y, Okamura K, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. Published online October 15, 2021. doi:10.1038/s41440-021-00754-7

Fengler K. Rommel K.P. Blazek S. et al.

A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).

Circulation. 139: 590-600https://doi.org/10.1161/CIRCULATIONAHA.118.037654Fischell T.A. Ebner A. Gallo S. et al.

Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience.

JACC Cardiovasc Interv. 9: 589-598https://doi.org/10.1016/j.jcin.2015.11.041Mahfoud F. Renkin J. Sievert H. et al.

Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension.

JACC Cardiovasc Interv. 13: 471-484https://doi.org/10.1016/j.jcin.2019.10.048Mahfoud F. Weber M. Schmieder R.E. et al.

Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications.

Am Heart J. 239: 90-99https://doi.org/10.1016/j.ahj.2021.05.015

Booth LC, Nishi EE, Yao ST, et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertens Dallas Tex 1979. 2015;65(2):393-400. doi:10.1161/HYPERTENSIONAHA.114.04176

Mauriello A. Rovella V. Borri F. et al.

Hypertension in kidney transplantation is associated with an early renal nerve sprouting.

Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 32: 1053-1060https://doi.org/10.1093/ndt/gfx069

Singh RR, McArdle ZM, Iudica M, et al. Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. Hypertens Dallas Tex 1979. 2019;73(3):718-727. doi:10.1161/HYPERTENSIONAHA.118.12250

Mulder J. Hökfelt T. Knuepfer M.M. Kopp U.C.

Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats.

Am J Physiol Regul Integr Comp Physiol. 304: R675-682https://doi.org/10.1152/ajpregu.00599.2012Mahfoud F. Böhm M. Schmieder R. et al.

Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry.

Eur Heart J. 40: 3474-3482https://doi.org/10.1093/eurheartj/ehz118Thomopoulos C. Parati G. Zanchetti A.

Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials.

J Hypertens. 32: 2285-2295https://doi.org/10.1097/HJH.0000000000000378Ettehad D. Emdin C.A. Kiran A. et al.

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Lancet Lond Engl. 387: 957-967https://doi.org/10.1016/S0140-6736(15)01225-8

Pietzsch J, Mahfoud F, Williams B, et al. CLINICAL EVENT REDUCTIONS IN HIGH-RISK HYPERTENSION PATIENTS TREATED WITH RENAL DENERVATION: A MODEL-BASED ESTIMATE BASED ON 36-MONTH DATA FROM THE GLOBAL SYMPLICITY REGISTRY. J Am Coll Cardiol. 2021;77(18, Supplement 1):1644. doi:10.1016/S0735-1097(21)03000-X

Geisler B.P. Egan B.M. Cohen J.T. et al.

Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.

J Am Coll Cardiol. 60: 1271-1277https://doi.org/10.1016/j.jacc.2012.07.029Chowdhury E.K. Reid C.M. Zomer E. Kelly D.J. Liew D.

Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.

Am J Hypertens. 31: 1156-1163https://doi.org/10.1093/ajh/hpy108

Liu H, Chen W, Lai Y, et al. Selective Renal Denervation Guided by Renal Nerve Stimulation in Canine. Hypertens Dallas Tex 1979. 2019;74(3):536-545. doi:10.1161/HYPERTENSIONAHA.119.12680

de Jong MR, Hoogerwaard AF, Gal P, et al. Persistent Increase in Blood Pressure After Renal Nerve Stimulation in Accessory Renal Arteries After Sympathetic Renal Denervation. Hypertens Dallas Tex 1979. 2016;67(6):1211-1217. doi:10.1161/HYPERTENSIONAHA.115.06604

Tsioufis K. Mahfoud F. Feyz L. Dimitriadis K. Zadok Y. Daemen J.

TCT-32 ConfidenHTTM system - diagnostic electrical mapping of renal nerves for optimizing renal denervation procedures.

J Am Coll Cardiol. 72: B14-B15https://doi.org/10.1016/j.jacc.2018.08.1113Feyz L. Theuns D. Bhagwandien R. et al.

Atrial fibrillation reduction by renal sympathetic denervation: 12 months’ results of the AFFORD study.

Clin Res Cardiol. 108: 1-9https://doi.org/10.1007/s00392-018-1391-3Steinberg J.S. Shabanov V. Ponomarev D. et al.

Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial.

JAMA. 323: 248-255https://doi.org/10.1001/jama.2019.21187Heidenreich P.A. Lee T.T. Massie B.M.

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials.

J Am Coll Cardiol. 30: 27-34https://doi.org/10.1016/s0735-1097(97)00104-6

留言 (0)

沒有登入
gif